Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:

NCT ID: NCT06174129 Completed - Atrial Fibrillation Clinical Trials

Prevalence and Factors Associated With Atrial Fibrillation in Patients With Type 2 Diabetes

Start date: June 1, 2022
Phase:
Study type: Observational

This case-control study was conducted at Burapha University Hospital. The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.

NCT ID: NCT06167616 Completed - Type 2 Diabetes Clinical Trials

Infections and Latent Autoimmune Diabetes in Adults

LADA
Start date: September 1, 2010
Phase:
Study type: Observational [Patient Registry]

Infections are proposed risk factors for type 1 diabetes in children. The investigators will examine whether a diagnosis of infectious disease also confers an increased risk of latent autoimmune diabetes in adults.

NCT ID: NCT06086912 Completed - Type 2 Diabetes Clinical Trials

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.

NCT ID: NCT05988957 Completed - Type 2 Diabetes Clinical Trials

Nutrition-Focused Approach During CGM Initiation: A Qualitative Study

Start date: August 1, 2023
Phase:
Study type: Observational

The purpose of the qualitative research is to provide a deeper understanding of the perspectives of people with type 2 diabetes (T2D) who received a nutrition-focused approach (NFA) when initiating continuous glucose monitor (CGM).

NCT ID: NCT05979142 Completed - Hypertension Clinical Trials

Community-based Primary Care Program Effects on Pharmacotherapy of Type 2 Diabetes and Hypertension in Peru

Start date: September 2011
Phase:
Study type: Observational

The goal of this observational study is to compare usual care to a community-based primary care program (having components of treatment decisions based on clinical guidelines, self-management education, community health workers, and free health care visits and medications) in low-income Peruvians with type 2 diabetes and/or hypertension. The main question[s] it aims to answer are: - Compared to pre-program usual care, does the program result in greater benefits, measured as greater proportions of patients with glucose and blood pressure control or maximal quantities and doses of medications? - Are there greater benefits when the program was provided at home compared to when the program was provided in a clinic? - Does longer participation in the program result in greater benefits? Participants will participate in: - Self-management education provided by community health workers. - Monitoring of healthy behaviors and glucose, blood pressure, and weight. - Receipt of free medications for blood pressure, glucose, and heart disease prevention.

NCT ID: NCT05977205 Completed - Type 2 Diabetes Clinical Trials

COVID-19 Glycemic Control Study

Start date: May 2, 2020
Phase:
Study type: Observational

Diabetes mellitus is a chronic disease characterized by the inability of the body to maintain normoglycemia. Treatment of diabetes relies mostly on diabetes self-management, requiring a large investment of time and energy on a daily basis. Psychological wellbeing, behavioral patterns and social context play a major role in diabetes self-management and glycemic control. Social isolation behavior (self-quarantining) may impact glycemic control by influencing daily routines, therapy adherence, physical activity, and self-measurement and eating behaviors. Therefore, a period of nationwide self-quarantine, such as during the lockdown issued during the COVID-19 outbreak in the Netherlands, may have a large effect on glycemic control in patients with diabetes. In this observational cross sectional study, we aim to assess the impact of long-term self-quarantine on glycemic control, diabetes self-management and distress in patients with type 1 and type 2 diabetes mellitus. A specific subgroup of patients with T1D are those with complicated diabetes who have received a pancreas or islet transplantation and use immunosuppression, having multiple risk factors for severe COVID-19. The impact of lockdown strategies on mental and physical health is expectedly even greater in patients at even higher risk for severe COVID-19. We therefore additionally investigated differences in behavioral, mental and physical implications of a nationwide lockdown on patients with type 1 diabetes with and without islet or pancreas transplantation. Measurements will be performed during the lockdown period. Patients will be asked to perform a fingerprick HbA1c measurement once, sent back to the LUMC by mail. Data from continuous or flash glucose monitoring devices will be collected according to standard clinical practice. Furthermore, patients will be asked to fill out an online questionnaire once on diabetes self-management behavior, well-being and distress, along with questions about health status, level of education, medication use, employment, social situation and the impact of self-quarantine on daily routines. In this questionnaire, we ask patients to compare certain aspects of their life (e.g. anxiety, stress, weight, physical activity, glycemic control) at the time of the lockdown to before the lockdown. Data on demographics, type of diabetes, weight, BMI and HbA1c prior to the COVID-19 outbreak will be derived from the patient's electronic health file.

NCT ID: NCT05937737 Completed - Type 2 Diabetes Clinical Trials

Serum FGF21 Levels and Dietary Total Antioxidant Capacity in Type 2 Diabetes

Start date: April 20, 2020
Phase: N/A
Study type: Interventional

This study aimed to evaluate the phytochemicals and total antioxidant capacity in the diets of individuals with type 2 diabetes and assess their relationship with glycemic parameters, as well as certain biochemical parameters and Fibroblast growth factor 21 (FGF21), which is an inflammatory marker. The study was conducted on a total of 80 individuals, including 40 patients with overweight or obesity (Body Mass Index (BMI) > 25 kg/m²) with type 2 diabetes aged between 18 and 64, and 40 healthy controls (BMI between 18.5-35 kg/m²). The individuals were followed for 12 weeks with an appropriate diet. Biochemical parameters, anthropometric measurements, and dietary intake records were monitored at specific intervals throughout the study. The phytochemical index and total antioxidant capacity of the individuals' diets were measured, and FGF21 was examined in the serum.

NCT ID: NCT05897216 Completed - Type 2 Diabetes Clinical Trials

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

Start date: July 14, 2023
Phase: Phase 1
Study type: Interventional

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, D150 and D029 for Healthy Subjects in Fed State

NCT ID: NCT05893576 Completed - Type 2 Diabetes Clinical Trials

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

Start date: May 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.

NCT ID: NCT05854875 Completed - Type 2 Diabetes Clinical Trials

Diabetes Remission After RYGBP and RYGBP With Fundus Resection

Start date: September 22, 2019
Phase: N/A
Study type: Interventional

The goal of this randomized clinical trial is to evaluate glycemic control in patients with morbid obesity and type 2 diabetes after Roux-en-Y gastric bypass (RYGBP) and RYGBP with fundus resection. The main questions to answer are: - Rate of diabetes remission and the role of the gastrointestinal hormones - Whether fundus resection leads to improved glycemic control Patients will randomly undergo typical RYGBP or RYGBP with fundus resection. Gastrointestinal hormones profile [ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), glucagon], glucose levels and insulin response will be measured preoperatively, at 6 months and at 12 months, during 120-min OGTT.